The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2018 | An update on the state-of-affairs of BiTEs in the world of AML
Marion Subklewe
• 2 Dec 2018
At the time of this publication, there are a variety of studies exploring the optimal dose of bi-specific T-cell engager (BiTE) therapies for acute myeloid leukemia (AML). At the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Marion Subklewe, MD, of the LMU Hospital Munich, Munich, Germany, provides an overview of ongoing studies, and discusses key observations.
